Introduction
CD19 is a transmembrane glycoprotein of the immunoglobulin superfamily, which participates in the communication of Blymphoid cells with their environment and the control of proliferation and differentiation in response to external signals. 1, 2 The protein is broadly expressed through most stages of B-cell maturation from early pro-B-cells onwards and is downregulated on plasma cells. It is not expressed outside the B-cell lineage. Many B-lymphoid malignancies display this antigen, including most pro-and pre-B-cell acute lymphoblastic leukemias (ALL), common ALL, non-Hodgkin-lymphomas (NHL), chronic B-lymphocytic leukemia (B-CLL) and hairy-cell leukemias (HCL 3 ). The antigen is not shed from the surface of malignant cells and is internalized after antibody binding. 4 Owing to these favorable properties, CD19 appears to be an attractive target for the treatment of B-cell malignancies with antibody-derived therapeutics. Consequently, whole unconjugated CD19 monoclonal antibodies (mAbs) have been used in preclinical and clinical studies, [5] [6] [7] [8] but to date have not achieved convincing clinical results. Their interaction with Fc-receptors has been improved through glyco-engineering, 9, 10 and further improvements through the use of fully human mAbs may still lead to the development of successful intact therapeutic CD19 antibodies in the future.
The clinically used CD20 mAb Rituximab owes its success largely to effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and the activation of complement. 11 However, interactions of therapeutic antibodies with Fc-receptors on a variety of effector cells can also cause detrimental effects. Bispecific antibodies targeting CD19 and CD3 showed potent effects against tumor cells in cell-culture assays but did not convince in clinical trials, 12, 13 probably in part because they were absorbed by Fc-receptors on other cells than the intended effector cells. 14 To reduce these undesired effects, recombinant bispecific antibody constructs have been produced, consisting of single-chain Fv antibody fragments (scFvs) specific for CD19 fused to scFvs directed against trigger molecules on effector cells. Typical trigger molecules used were CD3 on T lymphocytes and CD16 on natural killer (NK) cells. These molecules deliberately lacking Fc-portions were successful in cell-culture studies, and some are under current clinical investigation. [15] [16] [17] [18] To avoid the problems of CD19-specific agents relying on effector cells, we aimed here for an agent employing an effectorcell-independent mechanism of action. In certain therapeutic settings, effector cells may not be present in sufficient quality and numbers. There is a clearly stated need for CD19-specific agents, for example in the treatment of pediatric leukemias. At the end of a conditioning chemotherapy, the blast titer often is still not reduced far enough to provide a reasonable prospect for a successful outcome of a stem-cell transplantation. 19 In this situation, an effector-cell-independent agent such as an immunotoxin is desirable to further reduce the blast cell titer, because the effector cells have also been damaged by the conditioning regime.
Various immunotoxins specific for CD19 have been generated and tested for antileukemic effects. In the majority of cases, plant-derived toxins such as ricin, saporin and derivatives were used. [20] [21] [22] In clinical trials, these agents have not produced durable responses and often gave rise to dose-limiting toxicities, mostly in form of vascular leak syndrome (VLS 22, 23 ). In addition, neutralizing antibodies against the immunoconjugates were observed due to their murine origin and the plant-derived toxin components. Mutated variants of these toxins with greatly reduced binding to endothelial cells have been created, which caused fewer VLS symptoms in murine studies. 24 Another series of immunotoxins have been produced employing bacterial toxins such as a truncated version of Pseudomonas Exotoxin A (ETA 0 ) as the effector component. In these fusion proteins, the toxin component was fused to antibody fragments specific for a number of tumor cell target antigens. [25] [26] [27] [28] [29] Among the most advanced representatives of this generation is BL22, a CD22 antibody fragment coupled to ETA 0 . In clinical trials for the treatment of HCL, this agent showed convincing effects, with only about 25% of the patients developing neutralizing antibodies. 30 Here we have chosen to design an scFv-ETA 30 and thus we anticipated that this may also hold true for other target antigens such as CD19. Therefore, here we designed an scFv immunotoxin directed against CD19, in an attempt to combine the favorable characteristics of CD19 as a target antigen with those of ETA 0 as the toxic component.
Materials and methods

Bacterial strains and plasmids
Escherichia coli XL1-Blue (Stratagene, Amsterdam, the Netherlands) was used for the amplification of plasmids and cloning, and E. coli BL21 (DE3; Novagen, Inc., Madison, WI, USA) served for the expression of scFv-ETA 0 fusion proteins.
Patient samples and cell lines
Heparinized peripheral blood samples from B-CLL patients and a frozen bone marrow sample from a pediatric B-ALL patient (common pre-B-ALL) were obtained after receiving informed consent and with the approval of the Ethics Committee of the University of Erlangen-Nuremberg. Mononuclear cells (MNCs) were isolated using Lymphoflot (Biotest, Dreieich, Germany) Ficoll density centrifugation in Leukosep tubes (Greiner, Frickenhausen, Germany) according to the manufacturer's instructions. Primary cells and leukemia-derived cell lines Nalm-6 and Reh (pre-B-ALL), Namalwa (Burkitt-lymphoma), U937 (monocytic leukemia), CEM (T-ALL; DSMZ; German Collection of Microorganisms and Cell Lines, Braunschweig, Germany) and SEM 33 were cultured in Rosewell Park Memorial Institute (RPMI) 1640-Glutamax-I (Invitrogen, Karlsruhe, Germany) containing 10% fetal calf serum (FCS) and penicillin and streptomycin (Invitrogen) at 100 U/ml and 100 mg/ml, respectively.
Mice
Female NOD/SCID mice (M&B, Ry, Denmark) were maintained under sterile and standardized environmental conditions (22711C room temperature, 50710% relative humidity, 12 h light-dark cycle) and received autoclaved food and bedding (ssniff Spezialdiäten, Soest, Germany) and acidified (pH 4.0) drinking water ad libitum. All experiments were performed according to the German Animal Protection Law with permission from the responsible local authorities.
Construction and expression of CD19-Exotoxin A' fusion protein (CD19-ETA 0 )
The sequence coding for the CD19-specific scFv was excised from a previously cloned pAK100 vector construct 34 and cloned into the expression vektor pet27b( þ ) (Novagen, Inc.) as previously described, 29 resulting in the expression vector pet27b( þ )-STREP-His-CD19-ETA-KDEL. The CD19-ETA 0 fusion protein was expressed under osmotic stress conditions. 29 
Flow cytometric analysis
Binding of CD19-ETA 0 to cells was analyzed using a FACSCalibur FACS instrument and CellQuest software (Becton Dickinson, Mountain View, CA, USA). Cells (2.5 Â 10 5 ) were incubated for 30 min on ice with 20 ml of the immunotoxin at a concentration of 5 mg/ml. A non-related CD33-ETA 0 immunotoxin 29 served as control for background staining. The cells were washed with PBA (phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin (BSA) and 7 mM sodium azide) and then incubated with 50 ml of a polyclonal rabbit anti-Pseudomonas ETA serum (Sigma, Deisenhofen, Germany) diluted 1:250 in PBA. Cells were washed and then incubated with R-phycoerythrin (RPE)-conjugated goat anti-rabbit-immunoglobulin G (IgG) (Dianova GmbH, Hamburg, Germany) for 30 min. After a final wash, the cells were analyzed by flow cytometry. For competition experiments, the parental mAb 4G7 was coincubated with the immunotoxin in varying molar excess concentrations. For monitoring of surface expression of CD19 on primary patient cells, 5 Â 10 5 cells were incubated for 30 min with 10 ml of RPE-conjugated mouse anti-4G7 IgG (BD Pharmingen, Heidelberg, Germany). Mouse IgG1 served as an isotype control. After a final wash, the cells were analyzed as described above.
Measurement of cytotoxic effects of CD19-ETA
0
For dose response experiments, cells were seeded at 2.5 Â 10 5 /ml in 24-well plates, and immunotoxin was added at varying concentrations. Cell death was measured by staining nuclei with a hypotonic solution of propidium iodide (PI) as described. 35 The extent of cell death was determined by measuring the fraction of nuclei with subdiploid DNA content. Ten thousand events were collected for each sample. The effective concentration (EC 50 ) value was calculated using graph pad prism software (San Diego, CA, USA). To determine whether cell death was attributable to apoptosis, cells were seeded at 2.5 Â 10 5 /ml and treated with the immunotoxin. Whole cells were stained with FITC-conjugated Annexin V (Caltag Laboratories, Hamburg, Germany) and PI in PBS according to the manufacturer's protocols. For blocking experiments, a 20-fold molar excess of the parental antibody was added 30 min before addition of the immunotoxin. For assessment of synergistic induction of apoptosis by CD19-ETA 0 with valproic acid (VPA) and cyclosporin A (CsA), the cooperativity
index (CI) was determined by dividing the sum of apoptosis induced by single-agent treatments with apoptosis induced by the combination treatment. CI values of 1 were considered additive, valueso1 were considered synergistic. Cells were incubated with 100 ng/ml CD19-ETA 0 , 150 mg/ml (Nalm-6) or 100 mg/ml (Reh, SEM) VPA, respectively, or with a combination of both. For testing of CD19-ETA 0 in combination with CsA (Sigma), cells were incubated with 100 mg/ml CD19-ETA 0 , 6 mM (Nalm-6, Reh) or 10 mM (SEM) CsA, respectively, or with a combination of both. Apoptosis was assessed as described above. Statistical analyses were performed with Microsoft EXCEL software. P-values were obtained using two-tailed paired t-tests with a confidence interval of 95% for evaluation of the statistical significance of combination treatment compared to single-agent treatment. For experiments with primary patient samples, cells were seeded at 4 Â 10 5 /ml and treated with 1 mg/ml of the immunotoxins. Apoptosis was assessed as described above.
Western blot analysis
Full-length poly (ADP-ribose) polymerase (PARP) and its specific cleavage product were detected using a mouse anti-human PARP antibody (BD Pharmingen, Heidelberg, Germany). Western blots were performed with secondary antibodies coupled to horseradish peroxidase (Dianova, Hamburg, Germany). Enhanced chemiluminescence reagents (Amersham Pharmacia, Freiburg, Germany) were used for detection. For blocking experiments, cells were preincubated with a 10-fold excess of the parental 4G7 mAb.
Inhibition of tumor engraftment in mice
After one wash and resuspension in 100 ml of PBS, 10 6 Nalm-6 cells were injected intravenously into the lateral tail vein on day 0 of the experiment. Mice were then treated with 10 mg CD19-ETA 0 in PBS on day 3 and monitored for health status daily. Moribund mice were killed according to regulations. Survival times were recorded for evaluation of therapeutic efficacy by Kaplan-Meier analyses and median survival was determined. Statistical analyses were performed using the log-rank test.
Results
Generation and specific binding of CD19-ETA 0
The cDNA coding for the CD19-reactive scFv obtained by subcloning the 4G7 hybridoma 34 was fused to the coding sequence for truncated Pseudomonas Exotoxin A lacking the receptor-binding domain (ETA 0 ; Figure 1a ). The resulting polypeptide was expressed in E. coli and purified from periplasmic extracts by affinity chromatography. The CD19-immunotoxin bound to the CD19-positive human B-cell precursor leukemia cell line Nalm-6 in an antigen-specific manner. Binding was prevented by coincubation with increasing concentrations of the parental 4G7 mAb (Figure 1b) . Moreover, CD19-ETA 0 failed to bind to CD19-negative U937 cells, a monocytic leukemia-derived cell line, thus displaying CD19-restricted binding (Figure 1b (Figure 2c ). In addition, treatment of Nalm-6, Reh and Namalwa cells with CD19-ETA 0 for 24 h induced cleavage of PARP, a characteristic feature of apoptotic cells. Induction of apoptosis was prevented again by the parental antibody (Figure 2d ). In conclusion, CD19-ETA 0 induced apoptosis of CD19-positive leukemia-and lymphoma-derived cell lines in an antigen-restricted manner and was effective at low nanomolar concentrations.
Synergistic cytotoxic activity of CD19-ETA 0 with valproic acid and cyclosporin A The histone deacetylase inhibitor VPA is able to induce apoptosis of human leukemic cells. 36 To test for potential additive or synergistic effects of VPA and CD19-ETA 0 , the cell lines Nalm-6, Reh and SEM were treated for 72 h with either 100 mg/ml CD19-ETA 0 and 100 or 150 mg/ml VPA alone, or with a combination of both agents. Combination treatment resulted in significantly increased levels of apoptosis in all tested cell lines (Figure 3a) . To assess whether these effects were additive or synergistic, the CI was calculated. Whereas the effect on SEM cells was additive (CI: 1.0), cotreatment showed synergistic effects for Nalm-6 and Reh cells (CI: 0.9; 0.7).
CsA has been shown to enhance apoptosis in acute lymphoblastic leukemia cells induced by resveratrol, a polyphenolic phytoalexin. 37 To test whether CsA was also capable of sensitizing cells for the cytotoxic effects of CD19-ETA 0 , Nalm-6, 
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Reh, and SEM cells were treated with the immunotoxin for 48 h in the presence or absence of CsA. Combination treatment with 100 ng/ml CD19-ETA 0 and 6 or 10 mM CsA, respectively, resulted in the induction of significantly greater levels of apoptosis than single-agent treatment in all tested cell lines (Figure 3b) . The CI values for Nalm-6, Reh and SEM were 0.4, 0.5 and 0.6, respectively, demonstrating a synergistic cytotoxic effect of CD19-ETA 0 and CsA for all three tested cell lines.
Efficient induction of apoptosis in primary B-CLL and pre-B-ALL cells by CD19-ETA
0
To evaluate the cytotoxic potential of CD19-ETA 0 for primary cells from leukemia patients, MNCs from peripheral blood of four adult B-CLL patients were treated with 1 mg/ml CD19-ETA 0 or a control immunotoxin (CD33-ETA 029 ), and apoptosis was assessed by Annexin V and PI staining. CD19-ETA 0 induced apoptosis of 54% of cells from patient 1 above background levels of spontaneous lysis after treatment for 48 h. Similarly, after treatment for 72 h, the samples from patients 2, 3 and 4 showed an increase in apoptosis levels of 38, 50 and 67%, respectively, over the untreated control samples. Killing by CD19-ETA 0 was antigen-dependent, because samples treated with the control immunotoxin showed no increase in apoptosis (Figure 4a) . Altogether, the immunotoxin induced apoptosis in 12/12 primary samples from B-CLL patients (Table 1 ). For some of these patients, information concerning deletions of the p53 gene and their clinical responses to standard chemotherapy was available. No obvious correlation between these parameters and responsiveness to CD19-ETA 0 was evident, and although p53 deletion is often correlated with poor therapeutic response in B-CLL, 38 cells from all three patients showing such deletions responded to the immunotoxin.
CD19-ETA 0 also exhibited antigen-restricted cytotoxic activity towards primary common precursor B-ALL cells from the bone marrow of one pediatric patient. Here, the immunotoxin increased the number of apoptotic cells by 37%, from 36% in the untreated control samples to 73%, whereas the control immunotoxin showed no activity (Figure 4b ).
In vivo effects of CD19-ETA 0 in NOD/SCID mice xenotransplanted with Nalm-6 cells
To assess the anti-leukemic potential of CD19-ETA 0 in an animal model, the immunotoxin was evaluated in NOD/SCID mice xenotransplanted with Nalm-6 cells. The mice received an injection of 1 Â 10 6 cells into the tail vein on day 0. Three days after tumor cell challenge, a single dose of 10 mg of CD19-ETA 0 or an irrelevant immunotoxin (CD7-ETA
027
) was injected i.v., and mice were observed for hind leg paralysis and loss of body weight 420%. Mice treated with CD19-ETA 0 (n ¼ 14) survived significantly longer than mice treated with PBS (n ¼ 13, P ¼ 0.007) or the control immunotoxin (n ¼ 10, P ¼ 0.002; Figure 5 ). Median survival time of the CD7-ETA 0 -treated control group was 29.5 days compared to 52.5 days for the CD19-ETA 0 -treated group.
Discussion
Here we describe the antileukemic effect of a monovalent scFv-ETA 0 immunotoxin targeting CD19. The immunotoxin induced Fusion proteins with bacterial toxins have been reported to provoke neutralizing antibody responses in some patients, 30 and therefore it was desirable to attempt a combination treatment with an immunosuppressive agent. CsA, an immunosuppressive agent widely used in organ transplantation and in the treatment of autoimmune diseases, had been reported to induce apoptosis ). Moreover, CsA has been demonstrated to enhance sensitivity of leukemia cells towards resveratrol, a polyphenolic phytoalexin which is also able to decrease DC mt and induce apoptosis. 37 Interestingly, another Exotoxin A-based immunotoxin, besides inhibiting protein synthesis, was also shown to induce apoptosis by decreasing DC mt . 40 Therefore, we examined whether the activity of CD19-ETA 0 could further be enhanced by simultaneous treatment of leukemic cells with CsA. Our findings that CD19-ETA 0 and CsA acted together in a synergistic manner may be explained by a mutual reinforcement of the effects of both agents on the reduction of DC mt , a key event during apoptosis. The observed enhancement of the antileukemic effects of CD19-ETA 0 by the approved drugs VPA and CsA suggests that a combination treatment with well tolerable doses of each agent may be an attractive concept for potential future applications. Interestingly, another CD19-directed saporin-based immunotoxin has been shown to synergize with rituximab. 41 This further demonstrates the feasibility of effectively combining CD19-directed immunotoxins even with other antibody-based therapeutics.
The pro-B-ALL-derived cell line SEM, 33 carrying a t(4;11) chromosomal translocation, was not responsive to treatment with CD19-ETA 0 alone, but responded to combination treatment with the immunotoxin and CsA. Pediatric leukemia cells carrying a rearrangement of the MLL gene, in particular the t(4;11) translocation, often display increased resistance to apoptosis, presumably induced by the MLL-AF4 translocation breakpoint protein. This fusion protein probably is an inducer of antiapoptotic effects, because silencing of this protein in leukemic cells restored the sensitivity to apoptosis-inducing agents. 42 However, some agents are able to induce apoptosis even in such cells, including the plant-derived phenolic antioxidants resveratrol and carnosol. 43, 44 Therefore, the MLL-AF4 translocation breakpoint protein may increase resistance to apoptosis induced via some pathways, but not via the pathway triggered by these antioxidants. The breakpoint fusion protein may also inhibit the path to apoptosis, which is induced in other cells by treatment with CD19-ETA 0 alone. Unexpectedly, the combination treatment with CD19-ETA 0 and CsA was synergistic and not simply additive, suggesting that in these cells the pathway to death induced by CD19-ETA 0 , although dampened by the presence of the MLL-AF4 fusion protein, may have been partially reactivated by simultaneous treatment with CsA. This result opens the perspective that the scFv-ETA 0 immunotoxin, if it reached clinical applications, may benefit from combination with CsA, in particular for the treatment of pediatric ALL with rearrangement of the MLL gene.
CD19-ETA 0 eliminated not only established leukemia-and lymphoma-derived cell lines but also primary cells from B-CLL patients. Information regarding the responses of the B-CLL patients to alkylating agents and fludarabin and the status of their p53 alleles was available. In our study, 12/12 patients responded to treatment with CD19-ETA 0 , and the degree of their response showed no obvious correlation with their response to chemotherapeutics. Three patients had a p53 deletion, detectable by fluorescence in situ hybridization (FISH), which is correlated with poor clinical outcome, 38 and still responded to the agent. This suggests that CD19-ETA 0 may offer a benefit to B-CLL patients regardless of their response or resistance to commonly used chemotherapeutic agents. This perspective is attractive, because B-CLL patients do not respond to treatment with Rituximab equally well as NHL patients.
Moreover, CD19-ETA 0 demonstrated its antileukemic effect also on primary bone marrow cells from one pediatric precursor B-ALL patient. The child was diagnosed with common B-ALL and the cells did not express CD20 on their surface (data not shown), which is the case for the majority of pediatric B-cell precursor ALLs. 45 Thus, patients with CD20-negative precursor B-ALL may benefit in the future from CD19-directed immunotherapeutic approaches, such as the CD19-ETA 0 immunotoxin presented here.
Most leukemias are supposed to arise from leukemic stem cells (LSCs), which have the capacity for self-renewal and are thought to maintain the disease. Therefore, targeting those cell populations would be desirable. Although there have been reports that CD19 is not expressed on ALL LSCs, 46 there recently 6 Nalm-6 cells i.v. to induce systemic disease. In four separate experiments, mice were given a single dose of 10 mg CD19-ETA 0 (m; n ¼ 14), CD7-ETA 0 (n; n ¼ 10; P ¼ 0.002) or PBS ('; n ¼ 13; P ¼ 0.007) on day 3 and were then observed for hind leg paralysis and loss of body weight 420%. Proportions of surviving mice are graphed over time. P-values are given for differences in inhibition of tumor engraftment between CD19-ETA 0 and PBS or CD7-ETA 0 treatment, respectively. Statistical analysis was performed using the log-rank test.
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Finally, the CD19-ETA 0 protein also displayed an antileukemic effect in NOD/SCID mice xenotransplanted with human Nalm-6 cells in a setting suited to test for the prevention of engraftment. The immunotoxin significantly prolonged survival of treated mice compared to mice which received either PBS alone, or an irrelevant immunotoxin directed against CD7, with 5/14 CD19-ETA 0 -treated mice surviving the observation period of 100 days. Importantly, a single dose of 10 mg of CD19-ETA 0 given 3 days after inoculation of tumor cells was sufficient to achieve statistically significant extension of survival time and repeated injections of the immunotoxin may further improve these results. Taken together, these results indicate that CD19-ETA 0 inhibited engraftment of malignant cells in a systemic leukemia model, thereby supporting the promising cell-culture data obtained with this immunotoxin. In summary, the favorable properties of CD19-ETA 0 make this protein a promising candidate for further development towards clinical testing.
